China has assured that it will approve next month the first drug against covid-19 developed by a Chinese pharmaceutical company. The drug is based on the use of monoclonal antibodies, capable of neutralizing the virus.

According to Chinese state media, the treatment is the result of joint research between Tsinghua University, the Number Three People's Hospital in the city of Shenzhen, and the company Brii Biosciences, based in China and the United States, said the Global Times, the official newspaper of the Chinese Communist Party.

For Zhang Linqi, a professor at Tsinghua University School of Medicine, quoted by the newspaper, "the human body produces a large amount of antibodies, but not all of them have antiviral efficacy. Our research aims to select the strongest ones, so they can be used as drugs to treat infected patients."

According to the source, the drug will be suggested for use in treating mild or moderate cases of covid-19.